Testosterone Administration in Older Men

Endocrinology and Metabolism Clinics of North America

Volumn 42, Issue 2, 2013, Pages 271-286

  Matsumoto, Alvin M ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Diagnosis; Hypogonadism; Testosterone; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE RECEPTOR STIMULATING AGENT; GESTAGEN; GLUCOCORTICOID; OPIATE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

AGING; ANDROGEN DEFICIENCY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ERYTHROCYTOSIS; GYNECOMASTIA; HEMATOCRIT; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; MALE; MALE HYPOGONADISM; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDERED BREATHING; STEROID THERAPY; TESTOSTERONE BLOOD LEVEL;

AGING; ANDROGENS; DRUG MONITORING; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INDIVIDUALIZED MEDICINE; MALE; QUALITY OF LIFE; TESTOSTERONE;

EID: 84878150065     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.02.011     Document Type: Review

References (32)

1. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95(6):2536-2559.
2. Araujo A.B., Esche G.R., Kupelian V., et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007, 92(11):4241-4247.
3. Araujo A.B., O'Donnell A.B., Brambilla D.J., et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004, 89(12):5920-5926.
4. Wu F.C., Tajar A., Beynon J.M., et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010, 363(2):123-135.
5. Gray A., Feldman H.A., McKinlay J.B., et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991, 73(5):1016-1025.
6. Harman S.M., Metter E.J., Tobin J.D., et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001, 86(2):724-731.
7. Tajar A., Forti G., O'Neill T.W., et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010, 95(4):1810-1818.
8. Travison T.G., Araujo A.B., Kupelian V., et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007, 92(2):549-555.
9. Wang C., Catlin D.H., Demers L.M., et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004, 89(2):534-543.
10. Bremner W.J., Vitiello M.V., Prinz P.N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983, 56(6):1278-1281.
11. Plymate S.R., Tenover J.S., Bremner W.J. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 1989, 10(5):366-371.
12. Brambilla D.J., Matsumoto A.M., Araujo A.B., et al. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 2009, 94(3):907-913.
13. Brambilla D.J., O'Donnell A.B., Matsumoto A.M., et al. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 2007, 67(6):853-862.
14. Swerdloff R.S., Wang C., Cunningham G., et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000, 85(12):4500-4510.
15. Anawalt B.D., Hotaling J.M., Walsh T.J., et al. Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. J Urol 2012, 187(4):1369-1373.
16. Bolona E.R., Uraga M.V., Haddad R.M., et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82(1):20-28.
17. Fernandez-Balsells M.M., Murad M.H., Lane M., et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95(6):2560-2575.
18. Chrisp P., Sorkin E.M. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1991, 1(6):487-509.
19. Fowler J.E., Whitmore W.F. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981, 126(3):372-375.
20. Thompson I.M., Zeidman E.J., Rodriguez F.R. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990, 144(6):1479-1480.
21. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363(2):109-122.
22. Basaria S., Davda M.N., Travison T.G., et al. Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2013, 68(2):153-160.
23. Srinivas-Shankar U., Roberts S.A., Connolly M.J., et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010, 95(2):639-650.
24. Liu P.Y., Yee B., Wishart S.M., et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 2003, 88(8):3605-3613.
25. Sandblom R.E., Matsumoto A.M., Schoene R.B., et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983, 308(9):508-510.
26. Schneider B.K., Pickett C.K., Zwillich C.W., et al. Influence of testosterone on breathing during sleep. J Appl Physiol 1986, 61(2):618-623.
27. Coviello A.D., Lakshman K., Mazer N.A., et al. Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. J Clin Endocrinol Metab 2006, 91(11):4669-4675.
28. Dobs A.S., Meikle A.W., Arver S., et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999, 84(10):3469-3478.
29. Watts N.B., Adler R.A., Bilezikian J.P., et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012, 97(6):1802-1822.
30. Coviello A.D., Kaplan B., Lakshman K.M., et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008, 93(3):914-919.
31. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360(13):1310-1319.
32. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13):1320-1328.